Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

UPDATE ON THE POSSIBLE PRIVATISATION; END OF OFFER PERIOD; AND RESUMPTION OF TRADING

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the "Company") pursuant to Rule 3.7 of the Takeovers Code, Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 29 January 2021, 1 March 2021, 8 April 2021, 7 May 2021, 8 June 2021 and 9 July 2021 (the "Announcements") in relation to, among other things, the Possible Privatisation. Unless the context requires otherwise, capitalised terms used herein have the same meanings as those defined in the Announcements.

UPDATE ON THE POSSIBLE PRIVATISATION

The Board wishes to announce that the Company has been informed by Sinopharm Hongkong that it has decided not to proceed with the Possible Privatisation this time. Accordingly, the offer period in relation to the Possible Privatisation has ended on 11 August 2021.

END OF OFFER PERIOD

Pursuant to Rule 31.1(c) of the Takeovers Code, unless there is a material change of circumstances and with the consent of the Executive, Sinopharm Hongkong and parties acting in concert with it may not within six months from the date on which the offer period in relation to the Possible Privatisation ended (i.e. 11 August 2021) either:

(i) announce an offer or possible offer for the Company (including a partial offer which could result in Sinopharm Hongkong holding Shares carrying 30% or more of the voting rights of the Company); or

(ii) acquire any voting rights of the Company if Sinopharm Hongkong or persons acting in concert with it would thereby become obliged under Rule 26 of the Takeovers Code to make an offer.

RESUMPTION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange was halted from 9:00 a.m. on Wednesday, 11 August 2021 pending the release of this announcement. An application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares on the Stock Exchange with effect from 1:00 p.m. on Wednesday, 11 August 2021.

Shareholders and potential investors are advised to exercise caution when dealing in the Shares and/or other securities of the Company, and if they are in any doubt about their position, they should consult their professional adviser(s).

By order of the Board

China Traditional Chinese Medicine Holdings Co. Limited

WU Xian

Chairman

Hong Kong, 11 August 2021

As at the date of this announcement, the board of directors of the Company comprises twelve directors, of which Mr. WU Xian, Mr. WANG Xiaochun and Mr. YANG Wenming are executive directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive directors.

The directors of the Company jointly and severally accept full responsibility for the accuracy of information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in the announcement misleading.